Loading patent…
OwnerGeorg Fey, Karin Barbin +2inventors
InventorsGeorg Fey, Karin Barbin, Julia Stieglmaier, Matthias Peipp
Estimating the term…
A method of enhancing the antibody-dependent cellular cytotoxicity (ADCC) of a human or humanized CD19 antibody is disclosed. The antibody is produced in the presence of a beta.(1,4)-N-acetylglucosaminyltransferase III (GnTIII) enzyme, under conditions effective to produce in the antibody, an Fc fragment characterized by Asn297-linked oligosaccharides containing (i) at least 60% N-acetylglucosamine bisecting oligosasccharides, and (ii) at least 10% non-fucosylated N-acetylglucosamine bisecting oligosaccharides. Also disclosed is an anti-CD19 antibody, a composition produced by the method, a treatment method for cancers associated with malignant B-lineage cells, such as chronic lymphocytic leukemia, Non-Hodgkin lymphoma, and acute lymphoblastic leukemia, and a treatment method for autoimmune disease.
A method of enhancing the antibody-dependent cellular cytotoxicity (ADCC) of a human or humanized CD19 antibody, comprising
A method for treating a subject having a cancer associated with malignant B-lineage cells, such as chronic lymphocytic leukemia, Non-Hodgkin lymphoma, and acute lymphoblastic leukemia, comprising
A method for treating an autoimmune disease, such as multiple sclerosis, rheumatoid arthritis, and SLE, comprising
A human or humanized anti-CD19 antibody having an Fc fragment characterized by Asn297-linked oligosaccharides containing (i) at least 60% N-acetylglucosamine bisecting oligosasccharides, and (ii) at least 10% non-fucosylated N-acetylglucosamine bisecting oligosaccharides.
Dependencies are inferred from the claim text.